Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20662502 | 0.99 | MEN1 (0.56) | MEN1KMT2AMAPK1TSHRGAA | |
| SCHEMBL15924576 | 0.87 | MAPK1 (0.51) | MEN1KMT2AMAPK1TSHRGAA | |
| SCHEMBL12548974 | 0.85 | MEN1 (0.62) | MEN1KMT2AMAPK1TSHRGAA | |
| SCHEMBL1667486 | 0.84 | LMNA (0.49) | MEN1KMT2APOLBLMNASMN1; SMN2 | |
| SCHEMBL15921148 | 0.81 | PLA2G4A (0.49) | MEN1KMT2AMAPK1TSHRGAA | |
| SCHEMBL5515633 | 0.80 | MEN1 (0.65) | MEN1KMT2AMAPK1TSHRGAA | |
| SCHEMBL1667066 | 0.80 | RAB9A (0.51) | MEN1KMT2AMAPK1GAAPOLB | |
| SCHEMBL18649492 | 0.78 | MEN1 (0.59) | MEN1KMT2AMAPK1TSHRGAA | |
| SCHEMBL27868016 | 0.78 | MAPK1 (0.56) | MEN1KMT2AMAPK1TSHRGAA | |
| SCHEMBL7508636 | 0.78 | MAPK1 (0.56) | MEN1KMT2AMAPK1TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2019-08-06 | — | — | US | disclosed |
| EP-3431084-A1 | ANTIINFLAMMATORY 2-OXOTHIAZOLES | Avexxin AS (NO) | 2019-01-23 | — | — | EP | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-9597318-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | AVEXXIN AS (NO) | 2017-03-21 | — | — | US | disclosed |
| CN-103772312-A | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS | 2014-05-07 | — | — | CN | disclosed |
| CN-102647984-A | Anti-inflammatory 2-carbonylthiazoles and 2-carbonyloxazoles | AVEXXIN AS | 2012-08-22 | — | — | CN | disclosed |
| EP-2482815-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | Avexxin AS (NO) | 2012-08-08 | — | — | EP | disclosed |
| US-20110136879-A1 | COMPOUND | AVEXXIN AS (NO) | 2011-06-09 | — | — | US | disclosed |
| WO-2011039365-A1 | ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES | AVEXXIN AS (NO) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136879-A1 | COMPOUND | CBR1, CBR3, CCR1 | MEN1 2321/4885KMT2A 4796/4885MAPK1 1237/4885 |
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | MEN1 2314/4885KMT2A 4797/4885MAPK1 1246/4885 |
| US-10370344-B2 | 2-oxothiazole compounds and method of using same for chronic inflammatory disorders | CX3CR1, LTC4S, CBR1 | MEN1 3221/4885KMT2A 4706/4885MAPK1 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.